MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it ...

(NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...

In one particular study involving three patients with leg ulcers, Dooms-Goossens and Degreef discovered that the patients reacted to petrolatums on their leg ulcers despite having negative patch ...

The Department’s action is particularly good news for Medicare beneficiaries suffering from diabetic foot ulcers and venous leg ulcers. These patients will be able to access needed treatments in ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...